Clinical Trials

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03932331 2026-04-20

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

105 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04722172 2026-04-06

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02477696 2026-03-27

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02586857 2026-03-25

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

24 enrolled 10 charts

CNSLymphoidOther hematologic neoplasm

Glioblastoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02717611 2026-03-25

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

60 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

155 enrolled 16 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04624633 2026-02-25

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

29 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05057494 2026-02-18

MAJIC

607 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02029443 2026-02-06

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

306 enrolled 26 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06205498 2026-01-22

ARISE

Active not recruiting

151 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04198922 2025-11-05

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Other hematologic neoplasm

51 enrolled

Hematologic Neoplasms

NCT05971251 2025-10-01

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Phase 1 Active not recruiting

24 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 1 FDA

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02157324 2025-08-13

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04657094 2025-04-27

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Classical hematologyLymphoidOther hematologic neoplasm

4 enrolled 7 charts

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 2 FDA